Curis Propels Two Proprietary Drugs Forward In Plan To Retain Value
This article was originally published in The Pink Sheet Daily
Executive Summary
Cancer drug developer Curis held its first R&D day Oct. 3, a sign its early pipeline is maturing. The company outlined development plans for two proprietary drugs, an IAP inhibitor and a PI3K/HDAC inhibitor, both in early clinical development. As for partnering those assets, CEO Passeri said the company is looking to retain more value for them than it did for Erivedge.
You may also be interested in...
Deals of the Week: Sanofi/Selecta, Evotec/Probiodrug, Nestle/Chi-Med…
European economists meeting in London discuss drug innovation’s costs to the larger health system, research funding sources, and “sin taxes.”
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.